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Introduction: Guillain-Barré syndrome (GBS) is an immune-mediated disorder of the peripheral nervous system.
Respiratory failure requiring mechanical ventilation (MV) is a serious complication of GBS. Identification of
modifiable risk factors for MV and poor short-term prognosis in mechanically ventilated patients with GBS may
contribute to the individualized management and may help improve the outcome of the patients.
Methods: We retrospectively analyzed the clinical data of 541 patients who were diagnosed with GBS from 2003 to
2014. Independent predictors for MV and short-term prognosis in mechanically ventilated patients were identified
via multivariate logistic regression analysis.
Results: The mean age was 41.6 years with a male predilection (61.2 %). Eighty patients (14.8 %) required MV.
Multivariate analysis revealed that shorter interval from onset to admission (p < 0.05), facial nerve palsy (p < 0.01),
glossopharyngeal and vagal nerve deficits (p < 0.01) and lower Medical Research Council (MRC) sum score at nadir
(p < 0.01) were risk factors for MV; disease occurrence in summer (p < 0.01) was a protective factor. As to prognostic
factors, absence of antecedent infections (p < 0.01) and lower MRC sum score at nadir (p < 0.01) were predictors of
poor short-term prognosis in mechanically ventilated patients regardless of treatment modality. We further
investigated the predictors of poor short-term prognosis in patients requiring MV with different nadir MRC sum
scores. Combined use of intravenous corticosteroids with intravenous immunoglobulin (odds ratio 10.200, 95 %
confidence interval 1.068–97.407, p < 0.05) was an independent predictor of poor short-term prognosis in
mechanically ventilated patients with a nadir MRC sum score from 0 to 12 points, regardless of existence of
antecedent infection.
Conclusions: Clinical predictors of MV and poor short-term prognosis in mechanically ventilated GBS patients were
distinct. Add-on use of intravenous corticosteroids was a risk factor for poor short-term prognosis in mechanically
ventilated patients with a nadir MRC sum score from 0 to 12 points.Introduction
Guillain-Barré syndrome (GBS) is triggered by infectious
or noninfectious agents and is usually considered to be
an immune-mediated disorder of the peripheral nervous
system [1, 2]. As one of the common causes of acute
neuromuscular paralysis, GBS represents a clinical syn-
drome and most patients with GBS present with pro-
gressively flaccid, symmetric and ascending weakness of
extremities. Respiratory failure requiring mechanical* Correspondence: kangdingliu@163.com; drzhl@hotmail.com
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from 20 to 30 % [3–5]. Early prediction of MV in pa-
tients with GBS is of great importance to enable clini-
cians to tailor supportive care and individualized
treatment. Increasing studies have focused on the clin-
ical predictors of MV in patients with GBS. Multiple
clinical parameters have been found to serve as predic-
tors of MV from different studies, including time from
onset to admission of <7 days, inability to cough and
stand, inability to lift the elbows or head from the bed,
cranial nerve deficits, increased liver enzyme levels, anti-
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and the proximal/distal compound muscular amplitude
potential (p/d CMAP) ratio of the peroneal nerve [5–11].
Severe GBS, including that requiring MV, is usually associ-
ated with unfavorable residual sequelae or mortality, and
early identification of modifiable risk factors for the poor
prognosis may help decrease the incidence of residual se-
quelae and mortality. Risk factors for mortality in mechan-
ically ventilated patients with GBS include older age,
autonomic dysfunction and pulmonary complications
[12]. In addition, hypokalemia and bleeding were also
reported to be associated with increased incidence of mor-
tality in GBS patients requiring MV [13]. A previous study
demonstrated a seasonal variation in the recovery of
patients with GBS requiring MV [14]. Considering the
pivotal role of early identification of modifiable risk factors
for MV and poor prognosis, we herein investigated the
clinical predictors of poor short-term prognosis in mech-
anical ventilated patients with GBS, as well as the risk
factors for MV.
Methods
Study design and setting
This retrospective study was approved by the ethics
committee of the First Hospital of Jilin University,
Changchun, China. A written informed consent was ac-
quired from all the patients. The records of the patients
were anonymized and de-identified prior to analysis.
From 2003 to 2014, patients who were admitted to the
Department of Neurology of the First Hospital of Jilin
University and fulfilled the diagnostic criteria of GBS
were enrolled [15]. Patients were excluded if they met
one of the following exclusion criteria: younger than
16 years; diagnosed as either Miller Fisher syndrome,
chronic inflammatory demyelinating polyradiculoneuropa-
thy, Bickerstaff encephalitis, or critical illness polyneurop-
athy/myopathy (CIP/CIM) [16]. In addition, patients with
porphyric neuropathy were excluded as this neuropathic
condition typically occurs in association with other
features of an acute attack of hepatic porphyria and can
be differentiated from GBS by clinical features, such as a
proximal predilection of asymmetric weakness, accom-
panying psychiatric abnormalities, and laboratory exami-
nations (urine porphyrins) [17]. Patients who were
discharged within 3 days were ruled out because they
might not reach the nadir when discharged. Missing data
due to the short hospital stay is another reason for this ex-
clusion. For all the included subjects, data about age, sex,
preceding infections (mainly including upper respiratory
infection and diarrhea), time from onset to admission and
time from onset to nadir, clinical severity assessed by the
Hughes Functional Grading Scale (HFGS), muscle weak-
ness evaluated by the Medical Research Council (MRC)
sum score, sensory disturbances and reflexes in arms andlegs, cranial nerve deficits, autonomic dysfunctions (fluc-
tuating blood pressure, tachyarrhythmia and bradyar-
rhythmia, and abnormal sweating) and pain, as well as
treatment modality and complications during hospitalization
were collected. Intravenous immunoglobulin (IVIg) is the
first-line treatment option for GBS patients who were unable
to walk independently (HFGS ≥3) in our department, while
intravenous corticosteroids as an add-on therapy were ad-
ministrated to some of the severe patients as determined by
the neurologists. Of note, if the severe patients refused IVIg,
they were prescribed either intravenous corticosteroids or
supportive treatments.
Evaluation of clinical severity and functional impairment
The clinical severity and functional impairment were
evaluated for all the enrolled subjects. The HFGS score
was used to assess functional disability, which was de-
fined as follows [18]: 0, healthy state; 1, minor symptoms
and capable of running; 2, able to walk 5 m or more
without assistance but unable to run; 3, able to walk 5 m
across an open space with help; 4, bedridden or chair-
bound; 5, requiring assisted ventilation for at least part
of the day; 6, dead. Muscle weakness was evaluated by
the MRC sum score of six bilateral muscles in arms and
legs, ranging from 0 (tetraparalytic) to 60 (normal
strength) [19]. Nadir of disease was defined as the highest
HFGS score or the lowest MRC sum score.
Grouping and short-term prognosis assessment
Enrolled patients were divided into two groups accord-
ing to the requirement or not for MV, i.e., GBS patients
requiring MV (Group MV) and patients not requiring
MV (Group NV). In Group MV, the patients could be
further divided into two subgroups according to their
severity 4 weeks after the treatment, i.e., patients with a
good short-term prognosis (Subgroup 1) and patients
with a poor short-term prognosis (Subgroup 2). The
ability to walk with assistance at discharge (HFGS ≤3)
was considered to be a good short-term prognosis.
Statistical analysis
Statistical analysis was performed with SPSS version 17.0
software (SPSS, IBM, West Grove, PA, USA). Categorical
data are presented as proportions, while continuous data
are presented as means and standard deviations or
means and interquartile ranges depending on the distribu-
tion of the data. Differences in proportions were tested by
the Chi-square tests and differences in continuous vari-
ables were tested by student t-tests. Independent predic-
tors of MV and short-term prognosis in mechanically
ventilated patients with GBS were determined by using
multivariate logistic regression analysis. The final models
for independent predictors were the variables with statisti-
cally significant contributions obtained from univariate
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be significant.Results
Demographic features of enrolled patients with GBS
A total of 541 adult patients were enrolled. The mean
age was 41.6 years with a male preponderance (61.2 %).
Eighty (14.8 %) patients requiring MV during
hospitalization were placed into Group MV, while the
remaining 461 patients were in the Group NV. Compari-
sons between Group MV and Group NV are demon-
strated in Table 1. We found that cranial nerve
involvement was more common in Group MV (66.3 %
versus 39.9 %, p < 0.05), as was a longer hospitalization
period (38.7 versus 14.6, p < 0.05). Seasonal distribution
was also significantly different between the two groups,
as shown in Fig. 1a. More patients with MV (Group
MV) were admitted in winter while more patients
without MV (Group NV) were admitted in summer
(both p < 0.05). Time from onset to admission and
time from onset to nadir was both shorter in the
Group MV (3.5 versus 6.3 and 5.9 versus 7.6; both p <
0.05), as shown in Fig. 1b. In addition, muscle weakness
assessed by MRC sum score and disability evaluated by
HFGS indicated more severe disease severity in mech-
anically ventilated patients (Group MV) (MRC, 16.6
versus 41.0, p < 0.05; HFGS, 5 versus 3.0, p < 0.05;
Fig. 1c and d).Table 1 Comparisons between GBS patients with and without mec
Variable Group MV (n = 8
Age (years) 43.8 ± 16.7
Male 51 (63.8 %)
Antecedent infections 55 (68.75 %)
Cranial nerve involvement 53 (66.25 %)
Facial nerve 43 (81.1 %)
Glossopharyngeal and vagus nerves 30 (56.6 %)
Oculomotor and/or abducent nerve 12 (15 %)
Sensory disturbance 36 (45 %)
Autonomic dysfunction 7 (8.8 %)
Pain 7 (8.8 %)
Hyporeflexia or areflexia 79 (98.8 %)
Hospital stay (days) 38.7 ± 28.3
Treatment modality
IVIg 39 (48.8 %)
IVIg + intravenous corticosteroids 29 (36.2 %)
Intravenous corticosteroids 6 (7.5 %)
Supportive treatment 6 (7.5 %)
GBS Guillain-Barré syndrome, Group MV GBS patients with mechanical ventilation, G
intravenous immunoglobulinClinical predictors of MV
Independent predictors of MV in patients with GBS
were determined by multivariate logistic regression ana-
lysis. The univariate analysis revealed that the following
clinical parameters including seasons (summer and win-
ter), time from onset to admission, time from onset to
nadir, presence of cranial nerve involvement (facial,
glossopharyngeal and vagal nerve deficits), MRC sum
score at nadir and treatment modality (IVIg plus intraven-
ous corticosteroids) were statistically significant (p < 0.05).
Further, variables including time from onset to admission,
disease occurrence in summer, presence of cranial nerve
involvement (facial, glossopharyngeal and vagus nerve def-
icits), and MRC sum score at nadir were identified as sig-
nificant by the multivariate analysis. As shown in Table 2,
we found that shorter time from onset to admission, pres-
ence of facial, glossopharyngeal and vagal nerve deficits,
and lower MRC sum score at nadir were risk factors for
MV in patients with GBS, while disease occurrence in
summer was a protective factor.
Clinical predictors of poor short-term prognosis in
mechanically ventilated patients
Patients who were able to walk with assistance at dis-
charge (HFGS ≤3) were considered to have a good
short-term prognosis. Patients in Group MV were fur-
ther divided into two subgroups according to their
short-term prognosis at discharge, i.e., patients with a
good short-term prognosis (Subgroup 1) and patientshanical ventilation
0) Group NV (n = 461) p value
41.2 ± 15.3 >0.05
280 (60.7 %) >0.05
301 (65.3 %) >0.05
184 (39.91 %) <0.05
126 (68.5 %) <0.05
50 (27.2 %) <0.05
57 (12.4 %) >0.05
249 (54.0 %) >0.05
20 (4.3 %) >0.05
45 (9.8 %) >0.05
434 (94.1 %) >0.05






roup NV GBS patients did not require mechanical ventilation, IVIg
Fig. 1 Comparisons between patients with and without mechanical ventilation. a The seasonal distribution in GBS occurrence was different
between Group MV and Group NV. More GBS patients with mechanical ventilation were found in winter, while those without mechanical
ventilation were more common in summer (both p < 0.05). b Time from onset to admission and time from onset to nadir were both shorter in
Group MV (3.5 versus 6.3 and 5.9 versus 7.6; both p < 0.05). As assessed by c the MRC sum score and d HFGS, more severe disease severity was
found in Group MV (MRC, 16.6 versus 41.0; HFGS, 5 versus 3.0; both p < 0.05). Group MV GBS patients with mechanical ventilation, Group NV GBS
patients did not require mechanical ventilation, HFGS Hughes Functional Grading Scale, MRC Medical Research Council (sum score)
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aim was to identify the clinical predictors of poor short-
term prognosis in mechanically ventilated patients and
the treatment that might be associated with the short-
term prognosis, we excluded six patients who were
discharged within 3 days in Group MV. Among the
remaining 74 patients, 33 patients received IVIg treat-
ment, 29 patients were treated with IVIg combined with
intravenous corticosteroids, 6 patients received intraven-
ous corticosteroids and 6 patients received supportive
treatment instead of immunotherapy. Comparisons be-
tween the Subgroup 1 and Subgroup 2 are demonstrated
in Table 3. Glossopharyngeal and vagal nerve deficits
were higher in the good short-term prognosis group
(52.9 % versus 30 %, p < 0.05). Seasonal distribution and
the time from onset to admission and to nadir were not
different (p > 0.05) (Fig. 2a and b). Of note, the MRCTable 2 Independent predictors for mechanical ventilation in patien
Variable Regressio
Time from onset to admission −0.117 (0
Disease occurrence in summer −1.520 (0
Facial nerve involvement 0.921 (1.2
Glossopharyngeal and vagus nerves involvement 1.703 (2.5
MRC at nadir −0.099 (0
CI confidence interval, GBS Guillain-Barré syndrome, MRC Medical Research Councilsum score at nadir was significantly lower in the poor
short-term prognosis group compared with the good
short-term prognosis group (7.4 versus 26.9, p < 0.05;
Fig. 2c). As complications during hospitalization might
affect the prognosis of patients with GBS, we compared
the incidence of complications and found that complica-
tions occur comparably between the two groups (85.3 %
versus 92.5 %, p > 0.05; Fig. 2d).
Univariate analysis revealed that absence of antecedent
infections, presence of glossopharyngeal and vagal
nerve deficits, and the MRC sum score at nadir were
statistically significant variables in predicting poor
short-term prognosis in MV patients (p < 0.05). Fur-
thermore, absence of antecedent infections and the
nadir MRC sum score were also identified as poor
prognostic characteristics by multivariate analysis (p <
0.05) (Table 4).ts with GBS







Table 3 Comparisons between mechanically ventilated GBS patients with good and poor short-term prognoses
Variable Subgroup 1 (n = 34) Subgroup 2 (n = 40) p value
Age (years) 43.9 ± 16.3 41.9 ± 17.3 >0.05
Male 25 (73.5 %) 23 (57.5 %) >0.05
Antecedent infections 28 (82.4 %) 21 (52.5 %) >0.05
Cranial nerve involvement 26 (76.5 %) 24 (60 %) >0.05
Facial nerve 18 (52.9 %) 22 (55 %) >0.05
Glossopharyngeal and vagus nerves 18 (52.9 %) 12 (30 %) <0.05
Sensory disturbance 16 (47.1 %) 17 (42.5 %) >0.05
Autonomic dysfunction 3 (8.8 %) 2 (5 %) >0.05
Pain 3 (8.8 %) 4 (10 %) >0.05
Hyporeflexia or areflexia 33 (97.1 %) 39 (97.5 %) >0.05
Hospital stay (days) 31.0 ± 16.1 51.7 ± 31.2 <0.05
Treatment modality >0.05
IVIg 18 (52.9 %) 15 (37.5 %)
IVIg + intravenous corticosteroids 11 (32.4 %) 18 (45 %)
Intravenous corticosteroids 2 (5.9 %) 4 (10 %)
Supportive treatment 3 (8.8 %) 3 (7.5 %)
GBS Guillain-Barré syndrome, IVIg intravenous immunoglobulin, Subgroup 1 mechanically ventilated GBS patients with good short-term prognosis, Subgroup 2
mechanically ventilated GBS patients with poor short-term prognosis
Fig. 2 Comparisons of mechanically ventilated patients with good and poor short-term prognoses. a Seasonal distribution in the mechanically
ventilated GBS patients with good short-term prognosis (Subgroup 1) was similar to that in the poor-short-term prognosis (Subgroup 2) (spring,
32.4 % versus 20 %; summer, 17.6 % versus 30 %; autumn, 20.6 % versus 30 %; winter, 29.4 % versus 20 %; all p > 0.05). b Time from onset to admission
(3.5 versus 3.6, p > 0.05) and time from onset to nadir (5.8 versus 6.2, p > 0.05) were not significantly different. c MRC at nadir was significantly lower in
the poor short-term prognosis group compared with the good short-term prognosis group (26.9 versus 7.4, p < 0.05). d As the infection complications
during hospitalization were related to the prognosis of patients, we further compared the incidence of complications and found it was similar between
two groups (85.3 % versus 92.5 %, p > 0.05). MRC Medical Research Council (sum score)
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Table 4 Independent predictors for poor short-term prognosis in mechanically ventilated GBS patients
Variable Regression coefficient (95 % CI) p value Exp (B)
Antecedent infections −1.555 (0.050–0.892) <0.01 0.211
MRC at nadir −0.109 (0.852–0.943) <0.01 0.896
CI confidence interval, GBS Guillain-Barré syndrome, MRC Medical Research Council (sum score)
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independent predictor of poor short-term prognosis in
severely paralyzed patients requiring MV
We evaluated the effect of added steroid therapy to the
outcome in patients with severe muscle weakness at
nadir (40 patients, MRC sum score 0 to 12 points)
(Fig. 3). These treatments consisted of IVIg therapy (16
cases), IVIg combined with intravenous corticosteroids
(18 cases), intravenous corticosteroids alone (2 cases), or
supportive treatment alone (4 cases). Only the combin-
ation therapy was an independent predictor of poor
short-term prognosis regardless of the existence of ante-
cedent infections in these patients (odds ratio 10.200,
95 % confidence interval 1.068–97.407, p < 0.05). Thus
add-on use of intravenous corticosteroids predicted poor
short-term prognosis in severely paralyzed patients
requiring MV.
Discussion
In this study, we searched for predictors for MV and
short-term prognosis in mechanically ventilated patients
with GBS. Risk factors for MV included shorter interval
from onset to admission, presence of facial, glossopha-
ryngeal and vagal nerve deficits, and a lower MRC sum
score at nadir; disease occurrence in summer was a pro-
tective factor. For prognostic factors in patients requiringFig. 3 Distribution of mechanically ventilated patients with different nadir
from 0 to 12 points, corresponding to muscle strength less than 1/5 grade
points, 13 with a nadir MRC sum score from 25 to 36 points, 5 with a nadir
score from 49 to 60 pointsMV, we found that absence of antecedent infections and a
lower MRC sum score at nadir served as predictors of
poor short-term prognosis regardless of treatment op-
tions. Considering the impact of nadir MRC sum score on
prognosis, we further investigated the predictors for short-
term prognosis in mechanically ventilated patients with
different nadir MRC sum score ranges and found that
add-on use of intravenous corticosteroids was an inde-
pendent predictor for poor short-term prognosis of
patients with a MRC sum score from 0 to 12 points,
regardless of the existence of antecedent infection in
mechanically ventilated patients.
GBS is a potentially self-limiting disorder and most pa-
tients either recover completely or retain only minor re-
sidual symptoms. However, respiratory failure requiring
MV is a serious short-term complication of GBS with an
incidence of 20 to 30 % [3–5]. The incidence of MV in
our study was 14.8 %, which was lower than the above-
mentioned. This difference might be due to the distribu-
tion of different subtypes of GBS. Acute inflammatory
demyelinating polyneuropathy (AIDP) is common in
many European countries while acute motor axonal
neuropathy (AMAN) is particularly prevalent in East
Asia [20]. In particular, AIDP and AMAN are distinct
from each other in terms of the immunopathogenesis,
electrophysiological findings, pathological changes andMRC sum scores. There were 40 patients with a nadir MRC sum score
. In addition, 12 patients with a nadir MRC sum score from 13 to 24
MRC sum score from 37 to 48 points, and 4 with a nadir MRC sum
Wu et al. Critical Care  (2015) 19:310 Page 7 of 9clinical features; e.g., patients with AMAN less fre-
quently have cranial nerve involvement, and presence of
facial and/or bulbar weakness are predictors for MV in
patients with GBS [20, 21]. In this regard, the lower inci-
dence of MV in our study might be caused by the distri-
bution of the different subtypes of GBS in different
countries. Another reason for the disparity regarding the
incidence of MV is likely the different ratio of mildly af-
fected GBS patients (able to walk throughout the disease
course) that are diagnosed in different countries and
centers. The Department of Neurology of the First Hospital
of Jilin University is the largest center for the diagnosis and
treatment of GBS in northeast China. IVIg treatment is
usually initiated at a very early stage immediately a clinical
diagnosis is established, which may hinder the progression
of disease course.
Early prediction of MV is important, in that 60 % of
the patients with MV developed major complications,
including pneumonia, sepsis, gastrointestinal bleeding,
and so forth; early identification and intervention may
reduce the risk of complications and improve the out-
come of patients [22–25]. Accumulating studies have in-
vestigated the predictors of MV in patients with GBS.
We herein revealed that shorter interval from onset to
admission, facial nerve palsy, glossopharyngeal and vagus
nerve deficits, and lower MRC sum score at nadir were
risk factors for MV, which was consistent with previous
findings [5, 10, 11, 21]. Recently, Kannan Kanikannan
and colleagues have developed an NSB score model in-
cluding neck weakness, single breath count, and bulbar
palsy to accurately predict the requirement of MV [11].
In addition, we first identified that disease occurrence in
summer was a protective factor for MV with unclear
mechanisms. This finding warrants further investigation.
Despite the fact that IVIg and plasma exchanges are
effective options, patients with GBS still have non-
negligible neurological sequelae. Thus, early identifica-
tion of modifiable risk factors for prognosis in mechan-
ically ventilated patients may improve the outcome of
these patients. There have been few studies investigating
the prognostic factors of GBS patients who require MV.
Predictors for mortality in mechanically ventilated pa-
tients with GBS include older age, autonomic dysfunc-
tion and pulmonary complications, while a younger age
is correlated with a good outcome in these patients [12].
Hypokalemia and bleeding were also reported to be as-
sociated with increased incidence of mortality in GBS
patients requiring MV [13]. A seasonal variation has
been reported in the recovery of patients with GBS re-
quiring MV [14]. Patients admitted in spring usually had
the fastest recovery while those in winter had the slowest
recovery [14]. In our study, glossopharyngeal and vagus
nerve deficits were found in 80 (14.8 %) patients and
served as a predictor of MV which was consistent with aprevious study [21]. It is reasonable to speculate that
glossopharyngeal and vagus nerve deficits would be as-
sociated with a poor prognosis in patients with GBS. Of
note, the prognostic factors for GBS patients with and
without MV might be different. We found that more pa-
tients with glossopharyngeal and vagal nerve deficits in
the good short-term prognosis subgroup (p = 0.045), and
the univariate analysis also revealed that glossopharyn-
geal and vagal nerve deficits were statistically significant.
However, this was not validated by the multivariate ana-
lysis, implying that glossopharyngeal and vagal nerve
deficits did not serve as a predictor for poor short-term
prognosis in GBS patients who need MV. The prognos-
tic impact of glossopharyngeal and vagal nerve deficits
on GBS patients requiring MV still needs further investi-
gation. In addition, absence of antecedent infections (i.e.,
GBS is triggered by noninfectious agents, such as intra-
venous ganglioside) was found to serve as a predictor for
poor short-term prognosis in mechanically ventilated
patients with GBS. This finding is consistant with our
previous study which demonstrated more severe
manifestations and poorer short-term prognosis of
ganglioside-associated GBS [26], and is in accordance
with the study by Lin et al. [27]. They found that the
presence of prodromal upper respiratory tract infec-
tion was correlated with a better outcome; however,
their enrolled subjects were not limited to mechanic-
ally ventilated patients [27].
Although IVIg is proven effective treatment, GBS pa-
tients could have severe clinical signs or residual func-
tional deficits. Corticosteroids as immunosuppressant
and anti-inflammatory agents have been recommended
in treatment of severe or protracted GBS cases [28]. In
our study, most of the GBS patients requiring MV re-
ceived either IVIg or combination therapy. Previously,
we found that IVIg treatment was superior to combined
use of IVIg with intravenous corticosteroids in treating
mechanically ventilated patients with GBS (unpublished
data). In this study, we found a lower MRC sum score at
nadir predicted poor short-term prognosis in GBS pa-
tients requiring MV regardless of treatment options.
Considering the impact of nadir MRC sum score on
prognosis and that combination therapy might be detri-
mental to specific GBS populations, we further investi-
gated the prognostic factor in mechanically ventilated
patients with different nadir MRC sum score ranges. We
found that only the combination of IVIg with intraven-
ous corticosteroids was an independent predictor of
poor short-term prognosis in those patients with a nadir
MRC sum score from 0 to 12 points, i.e., who were se-
verely paralytic. The detrimental effects of corticoste-
roids might be due to their effect on denervated muscle,
or the inhibition of macrophage repair processes, or
hyperglycemia caused by corticosteroids [29–32]. In this
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mechanically ventilated patients who are severely para-
lytic. However, due to the limited sample size, predictors
of short-term prognosis in mechanically ventilated GBS
patients with different nadir MRC sum scores require
further investigation.
There are limitations to our study. First, although the
manifestations of CIP/CIM usually resemble those of
GBS, the albumino-cytologic dissociation in the cerebro-
spinal fluid and serum creatine kinase level contribute to
the differential diagnosis between GBS and CIP/CIM. How-
ever, the development of CIP/CIM during hospitalization
in severe GBS patients is difficult to identify, which might
adversely affect the prognosis. Second, as a retrospective
study, some clinical parameters which have been reported
to be predictors of MV were unavailable in our cohort,
such as anti-GQ1b antibodies, vital capacity, phrenic nerve
CMAP latency, and the p/d CMAP ratio of the peroneal
nerve [6, 9, 11]. Third, the sample size for stratified analysis
is too small to reach a conclusion with strong statistic sig-
nificance in our study. In addition, as axonal lesion patterns
have been demonstrated as one of the poor prognostic fac-
tors for patients with GBS [33], the electrophysiological
data might also serve as predictors for poor short-term
prognosis in GBS patients requiring MV. Similarly, dur-
ation of MV might be an important clinical parameter in
predicting the prognosis in patients requiring MV. How-
ever, due to the retrospective nature of our study, we failed
to make a follow-up on patients who still needed MV when
they were discharged and those who had not received elec-
trophysiological examination. Thus, the duration of MV
and the electrophysiological data were unavailable in some
patients. The prognostic value of duration of MV and sub-
types of GBS awaits further validation.
Conclusions
Clinical predictors for MV and poor short-term progno-
sis in mechanically ventilated patients with GBS were
distinct. Add-on use of intravenous corticosteroids was
an independent risk factor for poor short-term prognosis
in mechanically ventilated patients with a nadir MRC
sum score from 0 to 12 points.
Key messages
 The short interval from onset to admission,
presence of facial nerve palsy, glossopharyngeal and
vagal nerve deficits and lower nadir Medical
Research Council (MRC) sum score are risk factors,
while disease occurrence in summer is a protective
factor for mechanical ventilation (MV) in patients
with Guillain-Barré syndrome (GBS).
 As to prognostic factors, absence of antecedent
infections and lower MRC sum score at nadir arepredictors for poor short-term prognosis in mechan-
ically ventilated patients with GBS.
 Add-on use of intravenous corticosteroids is an
independent predictor of poor short-term prognosis
in mechanically ventilated GBS patients with a nadir
MRC sum score from 0 to 12 points, i.e., who were
severely paralytic.
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